Embolization treatment for meningioma
Official title: Therapeutic Endovascular Embolization for Intracranial Meningioma
Run by St. Olavs Hospital · NCT05416567 · Data updated 2026-11-12
This study is testing a new way to treat meningioma brain tumors using a method that could help reduce bleeding during surgery and improve outcomes for patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | St. Olavs Hospital Academic / other |
| Locations | 1 site (Trondheim) |
| Status | Recruiting |
| Started | October 10, 2022 |
| Main results expected | August 2027 |
| Study ends | August 2037 |
| Registry record updated | July 21, 2026 |
| Trial ID | NCT05416567 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a radiological diagnosis of typical intracranial meningioma that is growing or symptomatic.
✕Probably not a fit
Patients with previous treatment for meningioma, significant tumor-related complications, or other serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of endovascular embolization as a treatment for meningioma, a type of brain tumor that often requires intervention when it grows or causes symptoms. The approach aims to reduce intraoperative bleeding and improve clinical outcomes for patients undergoing treatment. By assessing both radiological and clinical results, the study seeks to expand treatment options for patients with meningioma, particularly in cases where traditional surgery or radiotherapy may not be ideal. The study includes patients diagnosed with typical intracranial meningioma who meet specific eligibility criteria.
Why it matters
Potential benefit: If successful, this treatment could provide a safer and more effective option for managing meningioma, potentially reducing the need for invasive surgery.
How similar studies have gone: While endovascular embolization is a recognized technique in certain cases, this specific application for meningioma is less commonly studied, indicating a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Radiological diagnose of typical intracranial meningioma (homogenous contrast enhancement or dural attachment) * Indication for treatment due to growth, symptoms or both * Tumor location suggestive of vascular supply via middle meningeal artery branches * Age 18 years or older * Karnofsky performance status of 90 or better (able to carry on normal activity and work) Exclusion Criteria: * Informed consent not possible (e.g. language barriers, aphasia, cognitive impaired) * Previously treated for meningioma * Intraosseous growth * Tumor related brain edema * Neurofibromatosis type 2 * Systemic cancer * Epilepsy * Progressive neurodegenerative disorder (eg. MS, Parkinsons disease) * History of psychiatric disorder * Unfit for participation for any other reason judged by the physician including patients * Contraindications to MRI * Allergic to contrast agents * Relative contraindications to endovascular treatment judged from CT angiography (tortoise carotid arteries, carotid stenosis, calcified aortic arch, anatomical vascular variants/anomalies suggesting increased risk with endovascular treatment) * DSA (Digital subtraction angiography) from carotid artery suggesting that significant vascular supply is from other vessels than the MMA.
Where it's running
-
St Olavs Hospital
Trondheim, Norway Recruiting
Study contacts
- Principal investigator: Ole Solheim, PhD — St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
- Study coordinator: Ole Solheim, PhD
- Email: ole.solheim@ntnu.no
- Phone: +4772575256
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combination therapy with IN10018 and dalpiciclib for progressive meningioma
This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.
-
JZP3507 (ONC206) for recurrent Grade 2/3 meningioma
A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.
-
Panitumumab-IRDye800 for guiding brain tumor surgery
A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.
-
Zanzalintinib for recurrent or progressive meningioma
This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.
-
Meningioma: How social factors and personal risks relate to health outcomes
This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.
-
Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures
This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.